ErbB receptors: from oncogenes to targeted cancer therapies - Test2 - elhamkhani - TriplyDB

ErbB receptors: from oncogenes to targeted cancer therapies

ErbB receptors: from oncogenes to targeted cancer therapies

http://www.wikidata.org/entity/Q24683709

about

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review MAPK scaffold IQGAP1 binds the EGF receptor and modulates its activation Targeting cellular metabolism to improve cancer therapeutics PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma Aptamers: A promising chemical antibody for cancer therapy Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?Progress of molecular targeted therapies for prostate cancers G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues Cannabinoids as therapeutic agents in cancer: current status and future implications Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains Therapeutic targets of triple-negative breast cancer: a review CDA: combinatorial drug discovery using transcriptional response modules Quantification and kinetic analysis of Grb2-EGFR interaction on micro-patterned surfaces for the characterization of EGFR-modulating substances Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors.Manipulating biological agents and cells in micro-scale volumes for applications in medicine.FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.Targeting the EGF receptor for ovarian cancer therapy.Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines Potential of Central, Eastern and Western Africa Medicinal Plants for Cancer Therapy: Spotlight on Resistant Cells and Molecular Targets.Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A-431) cells Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines Chemical genetics identifies small-molecule modulators of neuritogenesis involving neuregulin-1/ErbB4 signaling.Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.An analysis of trends and growth factor receptor expression of GI carcinoid tumors A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.Epidermal growth factor receptor copy number in potentially malignant oral disorders and oral squamous cell carcinoma: a short communication and preliminary study.Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression.Central role of the EGF receptor in neurometabolic aging.Coupled mutation finder: a new entropy-based method quantifying phylogenetic noise for the detection of compensatory mutations

P2860

Q21198850-8B3AF638-D8F0-4A45-8365-E7C4198CF09D Q24294200-4F9A1CFF-91DF-4564-906E-EBCD2039AA2C Q24596727-ECB64122-1E97-4AA3-8B8A-D767F417B26C Q26766293-F428DC31-9C46-49EE-8CF4-0044FABFF1C0 Q26766832-D1E4528F-2D2B-40C6-8575-037F15D0C0BE Q26769611-294428B0-C295-481E-A0F7-2A62F06B7C41 Q26823014-43218529-27EA-47CF-BBDA-0B4DBF0977D6 Q26825769-00F8B8FE-6627-4967-A661-CE075D99EF9F Q26866298-70A7EB80-D95F-48CE-BA1F-D355DE00A04E Q27027433-0EF3515E-9074-4D4D-B6F6-18547F7AA3BF Q27303674-C64971E1-0200-4FA8-9A0B-4A5696A96C72 Q27678732-07CDB483-FA4B-4138-9097-4408CE43556D Q28081591-E30E3AE1-BAE4-40F7-B3FF-C767C31CD8D6 Q28482122-158505E4-EDD1-4812-B835-E06E4B74E679 Q28541305-F81638F6-1636-427F-96B7-414D2F6A5D4F Q28547354-85059584-CD82-4EFE-9A7A-85ADA561683C Q30276647-E9E49C8F-76B4-456B-9D68-081C06342970 Q30356771-DD3C93E8-6614-4235-AA40-FB553A48015A Q30445677-2475E2F6-DC56-4C9B-85F2-9C8659FE4D04 Q32884377-E74DEA78-9435-4C9B-A948-121745C57A3E Q33275402-6AEDEB24-7287-47F5-B481-6B2A8B5DB7F8 Q33425039-45F33734-8741-4E52-BF61-A7E5898A84CB Q33570526-3232D722-61D8-40F0-93B7-8C48CCA9C89F Q33579653-77995544-05D3-49D3-841F-0949E327F0CC Q33605906-8BF01B07-E255-4BB1-9F99-F1DD2169C0E9 Q33680681-5E7CCB87-034E-4A1F-ACC2-322A01EDE37B Q33684453-01BDF3C9-EF90-44ED-A74D-5B705F120823 Q33708364-56C4E4D1-9658-44A2-B20D-88B49CAD138E Q33753279-CFF072D2-1C1D-4991-866F-5D8462105682 Q33772886-B067F4EF-1B66-439C-9802-D2FD991ED559 Q33822560-F35ED13C-CEEE-4ACC-831E-B29985E70FDF Q33863150-D03AA654-7BE4-4B22-AE76-0FDC61373D89 Q33942266-C9D31AAF-2708-4116-81F1-127C744B5E26 Q33966430-1A1C83D8-E257-4B85-AB4A-7F0F239E79B4 Q33985773-F1EDD399-490B-40A5-89F8-72C7E1058439 Q34018570-4ECFB198-FA0E-4A21-A82F-1988DD567F40 Q34195184-2DB885AA-B170-4876-9E00-D7CDC8CEABF0 Q34201388-B63D4B1F-62F0-4CBF-98C9-66FACE977BAA Q34285619-835394FF-01AE-4101-A2EB-BB0EBC0CF76D Q34410131-CC5B8579-DC18-4CB0-8BB8-E5ED6126EDF5

P2860

ErbB receptors: from oncogenes to targeted cancer therapies

http://www.wikidata.org/entity/Q24683709

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

ErbB receptors: from oncogenes to targeted cancer therapies

@ast

ErbB receptors: from oncogenes to targeted cancer therapies

@en

ErbB receptors: from oncogenes to targeted cancer therapies

@nl

type

label

ErbB receptors: from oncogenes to targeted cancer therapies

@ast

ErbB receptors: from oncogenes to targeted cancer therapies

@en

ErbB receptors: from oncogenes to targeted cancer therapies

@nl

prefLabel

ErbB receptors: from oncogenes to targeted cancer therapies

@ast

ErbB receptors: from oncogenes to targeted cancer therapies

@en

ErbB receptors: from oncogenes to targeted cancer therapies

@nl

P1433

Q24683709-09F6F113-7716-41F9-B3E9-8A461672CC3A

P1476

Q24683709-3008ED15-EF7B-47C0-8FBB-C1EA81D64761

P2093

Q24683709-6B6F283E-F770-4C01-A3A3-1FE04E760EF9

Q24683709-A4A63117-D72C-4A45-9711-95F9E2145B22

Q24683709-B6FFB670-5444-4A91-84F2-FF30947EFE97

Q24683709-DCA2B851-1981-4047-BDDE-0067DDA61844

Q24683709-E29FDBDD-1F7E-4CEB-992B-2B687E993879

Q24683709-F9C5F9D9-F293-49E8-B464-48D94E882EDB

P2860

Q24683709-077DB159-28E3-4BFF-AD22-BB146CE75EA7

Q24683709-0A6BED53-7423-4340-A291-D5E1124AC368

Q24683709-102038D2-FC32-483F-A782-F0216844D891

Q24683709-12924466-1CFC-49F5-9E0F-A5E138D1A312

Q24683709-13B04C7F-CCF8-473E-8B44-3388CF99B94F

Q24683709-142EADFE-9839-45DD-B08F-F1125DABAE9E

Q24683709-14BB1BB8-6D65-456F-83FA-148B15446D6F

Q24683709-1570108A-82A6-45D4-93F1-342C79A2224F

Q24683709-17AE751C-5DB2-4BF2-B323-9C3F3060EE31

Q24683709-19AEDD37-8E59-4A65-8694-74E8D0CE3695

P304

Q24683709-BDCF15E3-1DFB-40F0-9656-C956744A17AE

P31

Q24683709-B16BC807-0206-449E-A72E-B9843A87D823

P3181

Q24683709-26903E39-1497-4289-9256-4A2530A5ADB8

P356

Q24683709-D14BA4A3-9FD2-41B1-B451-BCEB2F91661C

P407

Q24683709-AF1EC927-9649-4C34-98C0-77D165620B80

P433

Q24683709-01020F2B-42E1-41F8-99A7-6AF81AF3AA0C

P478

Q24683709-0CE9CF36-9303-4433-B02A-6DBBF0F06E43

P50

Q24683709-164AFA40-8FBB-4B1C-9B4D-C3CD2C08D44D

Q24683709-7EBD2C14-68DA-4565-B11B-1ED8D309F13D

P577

Q24683709-04EAEDA0-0C52-4439-BADA-DD40553AAC26

P5875

Q24683709-B7362704-B7B3-4A6A-AE74-F2331EBC1ADE

P698

Q24683709-A87A094B-88C8-440A-8D6D-0B3059A12898

P932

Q24683709-F1803D7B-89DE-4CBE-B002-A6D5182C90AA

P3181

P356

P1433

Journal of Clinical Investigation

P1476

ErbB receptors: from oncogenes to targeted cancer therapies

@en

P2093

Alan Berezov

http://www.w3.org/2001/XMLSchema#string

Geng Zhang

http://www.w3.org/2001/XMLSchema#string

Hongtao Zhang

http://www.w3.org/2001/XMLSchema#string

Jeffrey Drebin

http://www.w3.org/2001/XMLSchema#string

Mark I Greene

http://www.w3.org/2001/XMLSchema#string

Ramachandran Murali

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions

A quantitative protein interaction network for the ErbB receptors using protein microarrays

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

Solution structure of human survivin and its binding interface with Smac/Diablo

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.

Humanization of an anti-p185HER2 antibody for human cancer therapy

P304

2051-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4052126

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI32278

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6166958

http://www.w3.org/2001/XMLSchema#string

P698

17671639

http://www.w3.org/2001/XMLSchema#string

P932

1934579

http://www.w3.org/2001/XMLSchema#string